2 Information about trifluridine–tipiracil

Marketing authorisation indication

2.1 Trifluridine–tipiracil (Lonsurf, Servier) is indicated for 'monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least 2 prior systemic treatment regimens for advanced disease'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for trifluridine–tipiracil.


2.3 The list price of trifluridine–tipiracil is £500 per pack of 20 tablets containing 15 mg of trifluridine and 6.14 mg of tipiracil, and £666.67 per pack of 20 tablets containing 20 mg of trifluridine and 8.19 mg of tipiracil (excluding VAT; BNF online, accessed October 2022).

2.4 The company has a commercial arrangement. This makes trifluridine–tipiracil available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)